IMF-001 / ImmunoFrontier - LARVOL DELTA

Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy. (PubMed, Cancer Immunol Immunother) - "Fifty-four patients with NY-ESO-1-expressing ESCC who underwent radical surgery following cisplatin/5-fluorouracil-based neoadjuvant chemotherapy were assigned to receive either CHP-NY-ESO-1 vaccination or observation as control. These results suggest that PIGR would play a major role in tumor immunity in an antigen-specific manner during NY-ESO-1 vaccinations. The IgA response may be relevant."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology • Squamous Cell Carcinoma • CTAG1B

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: ImmunoFrontier, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Breast Cancer • Esophageal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 (clinicaltrials.gov) - P1; N=23; Completed; Sponsor: ImmunoFrontier, Inc.; Active, not recruiting ➔ Completed; N=15 ➔ 23; Trial primary completion date: Aug 2013 ➔ Nov 2013

Clinical • Enrollment change • Trial completion • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B

Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. (PubMed, Cancer Immunol Immunother) - "In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials."

Clinical • Journal • Esophageal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CTAG1B